725 related articles for article (PubMed ID: 31605031)
1. Adaptive immunity: an emerging player in the progression of NAFLD.
Sutti S; Albano E
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
[TBL] [Abstract][Full Text] [Related]
2. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
[TBL] [Abstract][Full Text] [Related]
3. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).
Bruzzì S; Sutti S; Giudici G; Burlone ME; Ramavath NN; Toscani A; Bozzola C; Schneider P; Morello E; Parola M; Pirisi M; Albano E
Free Radic Biol Med; 2018 Aug; 124():249-259. PubMed ID: 29920340
[TBL] [Abstract][Full Text] [Related]
4. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
5. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.
Dallio M; Sangineto M; Romeo M; Villani R; Romano AD; Loguercio C; Serviddio G; Federico A
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406763
[TBL] [Abstract][Full Text] [Related]
6. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
Front Immunol; 2020; 11():609900. PubMed ID: 33574818
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
8. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
Koo SY; Park EJ; Lee CW
Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease.
Carranza-Trejo AM; Vetvicka V; Vistejnova L; Kralickova M; Montufar EB
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):783-796. PubMed ID: 33557653
[No Abstract] [Full Text] [Related]
10. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.
Barrow F; Khan S; Fredrickson G; Wang H; Dietsche K; Parthiban P; Robert S; Kaiser T; Winer S; Herman A; Adeyi O; Mouzaki M; Khoruts A; Hogquist KA; Staley C; Winer DA; Revelo XS
Hepatology; 2021 Aug; 74(2):704-722. PubMed ID: 33609303
[TBL] [Abstract][Full Text] [Related]
11. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicles as Inflammatory Drivers in NAFLD.
Srinivas AN; Suresh D; Santhekadur PK; Suvarna D; Kumar DP
Front Immunol; 2020; 11():627424. PubMed ID: 33603757
[TBL] [Abstract][Full Text] [Related]
13. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
14. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy.
Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory processes involved in NASH-related hepatocellular carcinoma.
Cannito S; Dianzani U; Parola M; Albano E; Sutti S
Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36691794
[TBL] [Abstract][Full Text] [Related]
17. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
Chen Y; Tian Z
Front Immunol; 2020; 11():1500. PubMed ID: 32765518
[TBL] [Abstract][Full Text] [Related]
18. Crucial role of T cells in NAFLD-related disease: A review and prospect.
Mao T; Yang R; Luo Y; He K
Front Endocrinol (Lausanne); 2022; 13():1051076. PubMed ID: 36457551
[TBL] [Abstract][Full Text] [Related]
19. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
[TBL] [Abstract][Full Text] [Related]
20. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
Zhou L; Shen H; Li X; Wang H
Front Immunol; 2022; 13():951406. PubMed ID: 35958574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]